DK1879873T3 - Neuroterapeutiske azolforbindelser - Google Patents
Neuroterapeutiske azolforbindelserInfo
- Publication number
- DK1879873T3 DK1879873T3 DK06768472.0T DK06768472T DK1879873T3 DK 1879873 T3 DK1879873 T3 DK 1879873T3 DK 06768472 T DK06768472 T DK 06768472T DK 1879873 T3 DK1879873 T3 DK 1879873T3
- Authority
- DK
- Denmark
- Prior art keywords
- neurotherapeutic
- stroke
- compounds
- azol compounds
- azol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 | |
| PCT/KR2006/001523 WO2006112685A1 (en) | 2005-04-22 | 2006-04-21 | Neurotherapeutic azole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1879873T3 true DK1879873T3 (da) | 2013-12-09 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06768472.0T DK1879873T3 (da) | 2005-04-22 | 2006-04-21 | Neuroterapeutiske azolforbindelser |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (da) |
| EP (1) | EP1879873B1 (da) |
| JP (1) | JP5035238B2 (da) |
| KR (1) | KR101286499B1 (da) |
| CN (1) | CN101228138B (da) |
| AR (1) | AR053065A1 (da) |
| AU (1) | AU2006237798B2 (da) |
| BR (1) | BRPI0607529B8 (da) |
| CA (1) | CA2606258C (da) |
| DK (1) | DK1879873T3 (da) |
| ES (1) | ES2441765T3 (da) |
| FI (1) | FIC20210018I1 (da) |
| MX (1) | MX2007013197A (da) |
| MY (1) | MY148589A (da) |
| NL (1) | NL301106I2 (da) |
| PL (1) | PL1879873T3 (da) |
| PT (1) | PT1879873E (da) |
| RU (1) | RU2418792C2 (da) |
| TW (1) | TWI398249B (da) |
| WO (1) | WO2006112685A1 (da) |
| ZA (1) | ZA200709994B (da) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| PL2155736T3 (pl) | 2007-05-14 | 2012-09-28 | Sk Biopharmaceuticals Co Ltd | Nowy związek, karbamoiloksyaryloalkanoiloarylopiperazyna, kompozycje farmaceutyczne zawierające ten związek oraz sposoby leczenia bólu, stanu lękowego i depresji przez podawanie tego związku |
| AU2008258599B2 (en) | 2007-06-05 | 2013-06-13 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| CN102026988B (zh) * | 2008-06-05 | 2013-07-03 | 爱思开生物制药株式会社 | 3-取代的丙胺化合物 |
| MX2011013982A (es) * | 2009-06-22 | 2013-01-29 | Sk Biopharmaceuticals Co Ltd | Metodo para la preparacion de este ( r ) - 1 - aril - 2 - tetrazolil - etilico de acido carbomico. |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| AU2010316106B2 (en) | 2009-11-06 | 2015-10-22 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| AU2010316172B2 (en) | 2009-11-06 | 2015-11-12 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| JP6232384B2 (ja) * | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| CA3046458A1 (en) * | 2016-12-14 | 2018-06-21 | Sk Biopharmaceuticals Co., Ltd. | Parenteral liquid preparation comprising carbamate compound |
| KR102635941B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| EP3556345B1 (en) * | 2016-12-14 | 2021-09-22 | SK Biopharmaceuticals Co., Ltd. | Orally disintegrated tablet comprising carbamate compound |
| KR102635936B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| EP3556363B1 (en) * | 2016-12-14 | 2024-03-06 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation or treatment of pruritus |
| CA3046297A1 (en) * | 2016-12-14 | 2018-06-21 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
| KR20200074152A (ko) | 2017-11-14 | 2020-06-24 | 에스케이바이오팜 주식회사 | 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| WO2019098628A1 (ko) * | 2017-11-14 | 2019-05-23 | 에스케이바이오팜 주식회사 | 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| EP3711756A4 (en) | 2017-11-14 | 2021-11-24 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELAX, OR TREAT MYOTONIA |
| KR20200074156A (ko) * | 2017-11-14 | 2020-06-24 | 에스케이바이오팜 주식회사 | 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도 |
| CN111432814A (zh) * | 2017-11-14 | 2020-07-17 | 爱思开生物制药株式会社 | 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途 |
| WO2019098634A1 (ko) | 2017-11-14 | 2019-05-23 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| KR20210047888A (ko) | 2018-09-21 | 2021-04-30 | 에스케이바이오팜 주식회사 | 카바메이트 화합물 및 이를 포함하는 배합물의 급성 스트레스 장애 또는 외상 후 스트레스 장애의 예방, 경감 또는 치료를 위한 용도 |
| US20210346348A1 (en) * | 2018-09-21 | 2021-11-11 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation or treatment of status epilepticus |
| MX2021004342A (es) * | 2018-10-19 | 2021-05-31 | Sk Biopharmaceuticals Co Ltd | Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia. |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| WO2021101295A1 (ko) * | 2019-11-22 | 2021-05-27 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법 |
| CN116322641A (zh) * | 2020-08-06 | 2023-06-23 | 爱思开生物制药株式会社 | 包含氨基甲酸酯化合物的固体口服组合物及其制备方法 |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| WO2003000247A1 (en) * | 2001-06-25 | 2003-01-03 | Sk Corporation | Carbamates of 2-heterocyclic-1,2-ethanediols |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en active Application Filing
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active IP Right Grant
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2606258A1 (en) | 2006-10-26 |
| MY148589A (en) | 2013-05-15 |
| ES2441765T3 (es) | 2014-02-06 |
| EP1879873A1 (en) | 2008-01-23 |
| EP1879873B1 (en) | 2013-10-09 |
| FIC20210018I1 (fi) | 2021-06-14 |
| ZA200709994B (en) | 2008-11-26 |
| RU2418792C2 (ru) | 2011-05-20 |
| NL301106I1 (nl) | 2021-06-02 |
| US20060258718A1 (en) | 2006-11-16 |
| PT1879873E (pt) | 2014-01-03 |
| BRPI0607529A2 (pt) | 2009-09-15 |
| CA2606258C (en) | 2014-01-14 |
| WO2006112685A1 (en) | 2006-10-26 |
| AU2006237798B2 (en) | 2012-07-12 |
| KR20080005437A (ko) | 2008-01-11 |
| EP1879873A4 (en) | 2011-06-15 |
| AR053065A1 (es) | 2007-04-18 |
| US7598279B2 (en) | 2009-10-06 |
| AU2006237798A1 (en) | 2006-10-26 |
| NL301106I2 (nl) | 2021-08-03 |
| KR101286499B1 (ko) | 2013-07-16 |
| CN101228138A (zh) | 2008-07-23 |
| MX2007013197A (es) | 2008-02-12 |
| TWI398249B (zh) | 2013-06-11 |
| JP5035238B2 (ja) | 2012-09-26 |
| TW200722085A (en) | 2007-06-16 |
| CN101228138B (zh) | 2012-11-21 |
| PL1879873T3 (pl) | 2014-03-31 |
| BRPI0607529B8 (pt) | 2021-05-25 |
| JP2008538557A (ja) | 2008-10-30 |
| BRPI0607529B1 (pt) | 2021-05-18 |
| RU2007143073A (ru) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1879873T3 (da) | Neuroterapeutiske azolforbindelser | |
| UA98629C2 (ru) | Соединения и способ модуляции киназ | |
| ATE469897T1 (de) | Indazolcarbonsäureamidverbindungen | |
| MX2011001384A (es) | Composiciones y metodos para tratar trastornos psiquiatricos. | |
| WO2005121065A3 (en) | DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS | |
| WO2006031556A3 (en) | Amidine substituted aryl aniline compounds | |
| EP3311818A3 (en) | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | |
| BRPI0515528A (pt) | n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central | |
| MA33241B1 (fr) | Composes pour le traitement de troubles metaboliques | |
| EP1961447A3 (en) | Treating depressive disorders with PKC activators | |
| RS51069B (sr) | Upotreba oksikodona za tretiranje visceralnog bola | |
| WO2006034296A3 (en) | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof | |
| MX2010004003A (es) | N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas. | |
| PL1853232T3 (pl) | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania | |
| LTC2805723I2 (lt) | Kladribino režimas, skirtas išsėtinei sklerozei gydyti | |
| MY143269A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder | |
| EP2086478A4 (en) | DYNAMIC MULDE, ESPECIALLY FOR THE TREATMENT OF HEAD AND NECK PAIN | |
| NZ548926A (en) | Inhibitors of TGF-R signaling for treatment of CNS disorders | |
| WO2005099702A3 (en) | R(-)-11-hydroxyaporphine derivatives and uses thereof | |
| EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
| MX2009011999A (es) | Extruidos con enmascaramiento del sabor mejorado. | |
| MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
| CA2587187A1 (en) | Treatment of mastitis with enrofloxacin | |
| NO20081835L (no) | Behandlingsmetoder ved bruk av oksytocin receptoragonister | |
| IL177861A0 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |